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ions can be developed to prevent these errors before they
ccur.
oi:10.1016/j.ijid.2010.02.2029
5.006
omparison of the effectiveness of low dose Indi-
avir/ritonavir (IDV/r) versus Atazanavir/ritonavir (ATV/r)
ased antiretroviral therapy in NNRTI experienced HIV-1
nfected patients in India
. Patel1,∗, A.K. Patel1, J.K. Patel1, E. Naik2, J. Duan2, R.
anjan1, S. Hamisu2
Vedanta Institute of Medical Sciences, 380009, Gujarat,
ndia
University of South Florida, Tampa, FL, USA
Background: Currently, data on the effectiveness of sec-
nd line antiretroviral regimens using IDV/r and ATV/r along
ith two back bone nucleosides in resource poor settings
s limited. It is important to compare the potency and efﬁ-
acy of each regimen in order to establish utility on clinical
utcomes. We sought to evaluate viro-immunologic deter-
inants of response to IDV400/r BID and ATV300/r QD in
re-treated HIV-infected patients.
Methods: Prospective cohort study on 441 patients who
xperienced immunological or clinical failure to ﬁrst line
NRTI-based treatment and were enrolled in a 96-week
tudy follow-up. Based on the patients ability to pay, 321
72.8%) and 120 (27.2%) patients were prescribed reg-
mens containing low dose of IDV/r 400/100mg BID or
TV/r 300/100mg QD with 2NRTI, respectively. Successful
mmunologic response to treatment was deﬁned by annual
ise in absolute CD4 count of 100/cmm or more from base-
ine, while successful virologic response was deﬁned by
VL < 400 copies/ml at 12 or 24 weeks after initiation of
reatment. Multivariate Cox Proportional Hazards Model was
sed to assess comparative effectiveness of treatment regi-
ens with correction for intra-cluster correlation by means
f the Robust Sandwich Estimator.
Results: Both the groups had similar age, sex and weight
istribution. (p = 0.302, 0.232 & 0.459 respectively). A total
f 63 patients (14.8%) had failed second line treatments, 53
atients (17.2%) were using IDV/r while 10 patients (8.5%)
ere on ATV/r. Patients who took IDV/r were more than
wice as likely to experience treatment failure as com-
ared to those on ATV/r (HR 2.18; 95% CI 1.14, 4.15). A
igniﬁcant treatment-response interaction was observed for
atient weight and prior combination of NRTI use. Success-
ul response was not different between the two groups when
atients weighed < 55 kg at baseline (log rank p value = 1.00)
n contrast to the ﬁndings among individuals weighing ‘‘55 kg
p = <0.0001). Patients with one NRTI recycled, ATV/r was
ound to be superior to IDV/r (p = 0.01) while among those
ith both NRTI recycled, there was no difference in response
o either group (p = 0.61).
Conclusion: We found that Successful response to second
ine therapy was twice as likely in the ATV/r group; however,
his difference was eliminated in patients less than 55 kg.
oi:10.1016/j.ijid.2010.02.2030
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RTI resistance proﬁle of the subtype F HIV-1 strains from
hildren and adolescents treated with multiple antiretro-
iral drugs
. Jugulete1,∗, M.L. Luminos2, M. Mardarescu3, D. Otelea4,
. Merisescu5
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, sector 2, Romania
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Disease ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Diseases, Bucharest, Romania
Background: The HIV epidemic in Romania is character-
zed by the existence of a large cohort of children and
dolescents that have been infected in the late eighties.
ost of these patients have been under treatment for the
ast ten years: all of them are currently on HAART but
heir majority has experienced a period (years) of either
onotherapy (AZT) or bitherapy (AZT with 3TC or ddC). This
tudy examines resistance proﬁles in the RT gene of HIV-1
trains obtained from these patients.
Methods: We have studied resistance tests on antiretro-
iral therapy of experienced children’s and adolescents with
IV infection and AIDS hospitalized in National Institute
f Infectious Diseases ‘‘Prof. dr. Matei Bal#’’. On these
atients we have evaluated: antiretroviral therapy, number
f antiretroviral schemes, the type of resistance muta-
ions selected on Nucleoside Reverstranscriptase Inhibitors
NRTI’s) and the implications on to established of antiretro-
iral therapy, also.
Results: The most frequent mutations were: M184V/I -
8.8%, T215F/Y — 74.4%, D67N — 68.2%, K219E/Q — 66.6%,
70R — 56.9%, M41L — 41.4%. The thymidine analogue
utations (TAMs) were common and frequently associated
ith M184V. Within the TAM group, T215F/Y was frequently
ssociated with D67N, K70R and/or K219E/Q. V75T/V was
ssociated with K219E but only seldom with K219Q. The mul-
iresistention on experimented HIV infected children was
.2% (Q151M, 69ins, K65R).
Conclusion: The mutation associations in the RT gene
f the subtype F HIV-1 strains are partly different from
hose communicated for the subtype B strains and therefore
equire further scrutiny.
oi:10.1016/j.ijid.2010.02.2031
5.008
mplementation of HLA-B*5701 genetic screening prior to
bacavir prescription in Georgia
. Dvali ∗, N. Chkhartishvili, L. Sharvadze, L. Dzigua, M.
archava, L. Gatserelia, T. TsertsvadzeInfectious Diseases, AIDS and Clinical Immunology Research
enter, Tbilisi, Georgia
Background: A hypersensitivity reaction to abacavir
evelops in approximately 2-8% of patients receiving this
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drug and is strongly associated with presence of the human
leukocyte antigen (HLA)-B*5701. Screening for HLA-B*5701
reduces the risk of developing an abacavir hypersensitivity
reaction. The carriage rate of HLA-B*5701 has not been stud-
ied in Georgia before 2009. Objective of the study was to
determine HLA-B*5701 prevalence in HIV-infected patients
in Georgia.
Methods: One hundred and sixty HIV-1 positive patients
attending Georgian Infectious Diseases, AIDS and Clinical
Immunology Research Center in 2009 within the national
treatment and care program were recruited for the study.
None of the patients had previously been treated with
abacavir. Blood samples were collected and screened for
HLA-B*5701 prior to abacavir prescription. Statistical anal-
yses were performed using SAS 9.1. Proportion with exact
95% conﬁdence interval (CI) and median with interquartile
range (IQR) are reported.
Results: Of 160 patients recruited 108 were male (67.5%)
and 42 (32.5%) - female. Median age of subjects was 32 years
(IQR 27—36). Nine patients tested HLA B*5701 positive —
5.6% (95% CI: 2.6—10.4%). Out of these nine patients 7 were
males (male prevalence: 6.5%, [95% CI: 2.6—12.9] %) and 2
females (female prevalence: 4.8% [95% CI: 0.6—16.2%]).
Conclusion: The ﬁrst prospective study of HLA-B*5701
prevalence in Georgia show similar results to the results
of other studies conducted in Caucasians. Abacavir still
remains one of the key drugs of antiretroviral regimens in
Georgia and other resource limited countries. Therefore,
prospective HLA-B*5701 screening should be implemented
in all settings where abacavir is widely used to guide selec-
tion of ART regimens and to reduce the risk of potentially
life threatening hypersensitivity reaction.
doi:10.1016/j.ijid.2010.02.2032
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Efﬁcacy of multivitamins containing phosphatidyl choline
in the mananegment of hepatotoxicity from antiretroviral
and/or antituberculous drugs
N. Ladep1,∗, N. Shehu2, A. Muazu2, P. Ugoagwu2, F.
Kakjing2, B. Badung2, C. Daniyan2, J. Idoko3
1 St George’s University, St George’s, St George’s, Grenada
2 AIDS Prevention Initiative Nigeria, Jos, Plateau, Nigeria
3 National Agency for the Control of AIDS, Abuja, FCT, Nige-
ria
Background: When hepatotoxicity develops in the course
of treatment with anti-tuberculosis and anti-retroviral
drugs, early improvement is important in order to con-
tinue speciﬁc treatment as early as possible. We aimed
to determine the efﬁcacy, safety and effect on quality of
life of phosphatidyl choline-containing multivitamin in the
management of antiretroviral and anti-tuberculosis hepato-
toxicity.
Methods: This was a randomized, single blinded placebo-
controlled pilot study. Included in the study were subjects
that had been enrolled to access drugs in the ARV pro-
gramme of Jos University Teaching Hospital (JUTH), who
had signed consent to participate in the parent PEPFAR
protocol and have started ARVs or antituberculous drugs.
Subjects received phosphatidyl choline-containing multivi-
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amin (Livolin forte®) or placebo (Vitamin B +Vitamin E as
n Livolin forte). Patients had either been on antitubercu-
ous or antiretroviral medications. Subjects on each arm
ere reviewed fortnightly or earlier if they had worsening
f symptoms. The liver function tests including ALT, AST
mprovements and deteriorations were noted and appro-
riate clinical decisions were taken according to standard
uidelines during the four weeks of each recruitment. The
ata were analysed and displayed in proportions and appro-
riate representations.
Results: Sixteen subjects completed the study. Five and
leven subjects were on placebo and livolin respectively.
he placebo recruitment was stopped after the ﬁfth sub-
ect due to deteriorations in liver function with associated
ncreased mortality in that group. Nine subjects were co-
nfected with Hepatitis B or C infection and one had triple
nfection of all three viruses. The baseline means ALT
or the livolin group and placebo arms were 313.19mM/L
nd 239.76mM/L respectively. There was signiﬁcant decline
f the mean ALT in the livolin group to 49.21mM/L and
8.17mM/L compared to placebo group 227.74mM/L and
29.24mM/L at two and four weeks respectively. While
oint pains reduced from 73.3% through 6.7% to 0% at the
nd of the study period in the Livolin group; the placebo
rm showed a ﬂuctuating course of 33.3%, 83.3% and 16.7%
espectively.
Conclusion: Phosphatidyl choline-containing multivita-
in demonstrated moderate beneﬁts to HIV infected
atients who develop hepatotoxicity to anti-tuberculosis or
ntiretroviral drugs when introduced early in their manage-
ent.
oi:10.1016/j.ijid.2010.02.2033
5.010
revalence of minor populations of drug-resistant HIV-1
n newly-diagnosed treatment-naïve individuals in Singa-
ore
.-J. Sun1,∗, P. Kaur1, Y.S. Leo2
Tan Tock Seng Hospital, Singapore, Singapore
Communicable Disease Centre, Tan Tock Seng Hospital, Sin-
apore, Singapore
Background: Primary drug-resistance in HIV-1, whether in
ajor viral populations or minor populations, is a signiﬁcant
linical and public health concern. Previous studies based on
onventional direct sequencing of virus samples have shown
hat HIV-1 primary drugresistance was insigniﬁcant in Singa-
ore. But it is not clear whether this is also true to the minor
IV-1 populations of the samples because direct sequencing
sually cannot detect resistance mutations in these popula-
ions. We performed this study to determine the prevalence
f primary drug-resistance in minor HIV-1 populations.
Methods: Twenty-four PBMC-associated virus samples
rom 24 newly-diagnosed treatmentnaïve patients were ana-
yzed. PCR products of pol gene that encompass the entire
rotease gene and two-third of the reverse transcriptase
ene were ampliﬁed using an in-house method. The PCR
roducts were then column-puriﬁed for direct sequencing
nd gel-puriﬁed for clonal sequencing. The viral gene cloning
as performed using the TOPO TA cloning kit (Invitrogen).
